XML 30 R5.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Consolidated Statements of Cash Flows (Unaudited) (USD $)
In Thousands
9 Months Ended
Jun. 30, 2011
Jun. 30, 2010
Cash flows from operating activities    
Net income $ 116,278 $ 34,717
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 12,336 14,029
Sale of intellectual property rights   (7,840)
Stock-based compensation 5,211 4,889
Amortization of premium on marketable securities 1,534 626
Undistributed (earnings) losses of joint ventures (1,618) 303
(Gain) loss on disposal of long-lived assets 24 (4)
Sale of contract manufacturing business (45,009)  
Loss on investment   191
Changes in operating assets and liabilities, net of acquisitions and disposals:    
Accounts receivable (461) (33,946)
Inventories (11,248) (33,683)
Prepaid expenses and other current assets 3,245 (3,065)
Accounts payable (11,812) 44,256
Deferred revenue (1,410) 1,598
Accrued warranty and retrofit costs (638) 1,769
Accrued compensation and benefits (72) (2,433)
Accrued restructuring costs (2,943) (3,043)
Accrued expenses and other 3,802 (482)
Net cash provided by operating activities 67,219 17,882
Cash flows from investing activities    
Purchases of property, plant and equipment (4,163) (1,908)
Purchases of marketable securities (145,821) (95,722)
Sale/maturity of marketable securities 78,644 67,492
Increase in restricted cash (760)  
Proceeds from the sale of the contract manufacturing business 75,664  
Proceeds from assets sold 4,372  
Acquisition of RTS Life Sciences, net of cash acquired (3,381)  
Proceeds from the sale of intellectual property rights   7,840
Purchase of intangible assets   (892)
Other   243
Net cash provided by (used in) investing activities 4,555 (22,947)
Cash flows from financing activities    
Proceeds from issuance of common stock, net of issuance costs 681 609
Net cash provided by financing activities 681 609
Effects of exchange rate changes on cash and cash equivalents 837 (542)
Net increase (decrease) in cash and cash equivalents 73,292 (4,998)
Cash and cash equivalents, beginning of period 59,823 59,985
Cash and cash equivalents, end of period $ 133,115 $ 54,987